Found: 4
Select item for more details and to access through your institution.
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E117, doi. 10.1002/ajh.26449
- By:
- Publication type:
- Article
The real-world outcomes of multiple myeloma patients treated with daratumumab.
- Published in:
- PLoS ONE, 2021, v. 16, n. 10, p. 1, doi. 10.1371/journal.pone.0258487
- By:
- Publication type:
- Article
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 521, doi. 10.1002/hon.2906
- By:
- Publication type:
- Article
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 1006, doi. 10.1002/jha2.774
- By:
- Publication type:
- Article